Douglas P. Baker's most recent trade in OptimizeRx Corp was a trade of 10,000 Common Stock done at an average price of $7.5 . Disclosure was reported to the exchange on Oct. 5, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 05 Oct 2021 | 10,000 | 44,796 (0%) | 0% | 7.5 | 75,100 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 10,000 | 34,699 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 82.35 per share. | 05 Oct 2021 | 10,000 | 34,796 (0%) | 0% | 82.4 | 823,500 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 84.22 per share. | 05 Oct 2021 | 4,000 | 34,796 (0%) | 0% | 84.2 | 336,880 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 74.66 per share. | 28 Sep 2021 | 2,000 | 38,796 (0%) | 0% | 74.7 | 149,320 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 70.59 per share. | 21 Sep 2021 | 4,000 | 40,796 (0%) | 0% | 70.6 | 282,360 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 65.57 per share. | 14 Sep 2021 | 3,768 | 44,796 (0%) | 0% | 65.6 | 247,068 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 10,000 | 44,699 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 67.25 per share. | 07 Sep 2021 | 10,000 | 48,564 (0%) | 0% | 67.3 | 672,500 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 07 Sep 2021 | 10,000 | 58,564 (0%) | 0% | 7.5 | 75,100 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 70.53 per share. | 07 Sep 2021 | 2,232 | 48,564 (0%) | 0% | 70.5 | 157,423 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 66.62 per share. | 31 Aug 2021 | 4,000 | 50,796 (0%) | 0% | 66.6 | 266,480 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 58.45 per share. | 20 Aug 2021 | 5,000 | 58,796 (0%) | 0% | 58.5 | 292,250 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 61.50 per share. | 20 Aug 2021 | 4,000 | 54,796 (0%) | 0% | 61.5 | 246,000 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 63.27 per share. | 13 Aug 2021 | 5,000 | 67,796 (0%) | 0% | 63.3 | 316,350 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 58.46 per share. | 13 Aug 2021 | 4,000 | 63,796 (0%) | 0% | 58.5 | 233,840 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 64.31 per share. | 09 Aug 2021 | 10,000 | 64,796 (0%) | 0% | 64.3 | 643,100 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 10,000 | 54,699 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 09 Aug 2021 | 10,000 | 74,796 (0%) | 0% | 7.5 | 75,100 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 64.50 per share. | 09 Aug 2021 | 2,000 | 72,796 (0%) | 0% | 64.5 | 129,000 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 54.93 per share. | 03 Aug 2021 | 2,000 | 74,796 (0%) | 0% | 54.9 | 109,860 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 52.58 per share. | 27 Jul 2021 | 3,000 | 76,796 (0%) | 0% | 52.6 | 157,740 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 50.90 per share. | 20 Jul 2021 | 3,000 | 79,796 (0%) | 0% | 50.9 | 152,700 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 56.05 per share. | 08 Jul 2021 | 13,435 | 69,361 (0%) | 0% | 56.1 | 753,032 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2021 | 13,435 | 64,699 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. | 08 Jul 2021 | 13,435 | 82,796 (0%) | 0% | 2.5 | 33,050 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 63.00 per share. | 28 Jun 2021 | 3,421 | 82,796 (0%) | 0% | 63 | 215,523 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 24 Jun 2021 | 4,000 | 86,217 (0%) | 0% | 60 | 240,000 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. | 07 Jun 2021 | 14,500 | 90,217 (0%) | 0% | 2.5 | 35,670 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 14,500 | 78,134 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 52.62 per share. | 07 Jun 2021 | 14,500 | 75,717 (0%) | 0% | 52.6 | 762,990 | Common Stock (pursuant to 10B5-1 plan) |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. | 18 May 2021 | 14,500 | 90,217 (0%) | 0% | 2.5 | 35,670 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 14,500 | 92,634 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 45.85 per share. | 18 May 2021 | 14,500 | 75,717 (0%) | 0% | 45.9 | 664,825 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 47.25 per share. | 29 Jan 2021 | 5,032 | 85,902 (0%) | 0% | 47.3 | 237,762 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 29 Jan 2021 | 4,315 | 90,217 (0%) | 0% | 7.5 | 32,406 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 4,315 | 107,134 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 13 Jan 2021 | 5,000 | 90,937 (0%) | 0% | 7.5 | 37,550 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 5,000 | 96,993 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 38.89 per share. | 13 Jan 2021 | 5,000 | 85,937 (0%) | 0% | 38.9 | 194,450 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 14,456 | 116,449 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.88 per share. | 04 Jan 2021 | 8,334 | 82,371 (0%) | 0% | 32.9 | 274,022 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. | 04 Jan 2021 | 4,566 | 86,937 (0%) | 0% | 2.5 | 11,232 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 4,566 | 105,993 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 4,000 | 101,993 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 04 Jan 2021 | 4,000 | 90,937 (0%) | 0% | 7.5 | 30,040 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2020 | 15,000 | 110,559 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. | 11 Nov 2020 | 15,000 | 90,705 (0%) | 0% | 2.5 | 36,900 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 24.05 per share. | 11 Nov 2020 | 15,000 | 75,705 (0%) | 0% | 24.1 | 360,750 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 02 Sep 2020 | 10,000 | 80,705 (0%) | 0% | 20 | 200,000 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2020 | 10,000 | 125,559 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. | 02 Sep 2020 | 10,000 | 90,705 (0%) | 0% | 2.5 | 24,600 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 13 Aug 2020 | 10,000 | 100,671 (0%) | 0% | 18 | 180,000 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2020 | 10,000 | 135,559 | - | - | Stock Option | |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. | 13 Aug 2020 | 10,000 | 110,671 (0%) | 0% | 2.5 | 24,600 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. | 06 Aug 2020 | 10,000 | 110,671 (0%) | 0% | 2.5 | 24,600 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 17.01 per share. | 06 Aug 2020 | 10,000 | 100,671 (0%) | 0% | 17.0 | 170,100 | Common Stock |
| OptimizeRx Corp | Douglas P. Baker | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2020 | 10,000 | 145,559 | - | - | Stock Option |